This study investigated the impact of metabolic disorders (milk fever and ketosis) and mastitis on dairy cow reproduction. The researchers found that milk fever was associated with increases in days to first service, services per conception, and a decrease in conception risk. Ketosis was linked to increases in days open and culling rates. Mastitis reduced pregnancy rates and increased abortion risk. The mechanisms by which these diseases negatively influence fertility include alterations in uterine function, ovarian blood flow, gastrointestinal motility, dry matter intake, and calcium absorption as well as increased inflammation.
Pregnancy markers for early pregnancy diagnosisVarij Nayan
“Detection of the pregnant/ non-pregnant cow/ buffalo, heifer, as soon as possible after a successful/ unsuccessful insemination, is important to ensure good reproductive and / productive performance in dairy and beef animals”
-Omics revolution and integration of all -omics sciences with a systems approach could help find solutions towards finding early pregnancy biomarkers.
Dairy Reproduction: Identifying Problems and Solutions for Your HerdDAIReXNET
Ray Nebel of Select Sires, Inc. presented this information for DAIReXNET on March 17, 2014. A recording of the full presentation can be found at http://www.extension.org/pages/15830/archived-dairy-cattle-webinars#.Uyigy86nbZU,
The science of synchronization of estrus and ovulation in females has made great strides.
Several protocols that allow producers to precisely schedule insemination of groups of females are available for fixed-time insemination in females.
Pregnancy markers for early pregnancy diagnosisVarij Nayan
“Detection of the pregnant/ non-pregnant cow/ buffalo, heifer, as soon as possible after a successful/ unsuccessful insemination, is important to ensure good reproductive and / productive performance in dairy and beef animals”
-Omics revolution and integration of all -omics sciences with a systems approach could help find solutions towards finding early pregnancy biomarkers.
Dairy Reproduction: Identifying Problems and Solutions for Your HerdDAIReXNET
Ray Nebel of Select Sires, Inc. presented this information for DAIReXNET on March 17, 2014. A recording of the full presentation can be found at http://www.extension.org/pages/15830/archived-dairy-cattle-webinars#.Uyigy86nbZU,
The science of synchronization of estrus and ovulation in females has made great strides.
Several protocols that allow producers to precisely schedule insemination of groups of females are available for fixed-time insemination in females.
Dan McFarland, an Agricultural Engineering Extension Educator for Penn State University, presented this material for DAIReXNET on January 14, 2015.
Find more information at http://www.extension.org/pages/15830/archived-dairy-cattle-webinars
Dr. Stephen LeBlanc presented this for DAIReXNET as part of our educational video series. View the full presentation at https://www.youtube.com/watch?v=IH4vPuOTFyM
How to Cure Ovarian Cysts Without Surgery ????. How to Cure Ovarian Cysts Without Surgery - Learn How to Cure Ovarian Cysts Without Surgery
Ovarian cyst treatment - step step guide, Discover 3-step home treatment program permanent relief ovarian cysts polycystic ovary syndrome (pcos)..
Ovarian cyst - wikipedia, free encyclopedia, Classification . ovarian cysts classified variant normal menstrual cycle, called functional cyst, .. Natural ovarian cyst cures - ovarian cyst treatment, Dear ovarian cyst sufferer, laura hennings 6 years suffered terrible ovarian cysts incredible pain ruining life..
Dr. Milo Wiltbank presented this for a DAIReXNET webinar on Wednesday, March 2, 2016. The full presentation recording can be found at http://bit.ly/1wb83YV.
Similar to Impact of Metabolic Disorders and Mastitis on Reproduction (20)
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
NVBDCP.pptx Nation vector borne disease control program
Impact of Metabolic Disorders and Mastitis on Reproduction
1. Impact of Metabolic Disorders and
Mastitis on Reproduction
Amin Ahmadzadeh*, Joseph C. Dalton
Animal and Veterinary Science Department
University of Idaho
2. Introduction
Reproductive disorders such as dystocia,
retained placenta, ovarian cysts and
metritis can decrease reproductive
performance of dairy cows
The effects of other diseases, such as
metabolic disorders and mastitis, on dairy
cow fertility have not been quantified
3. Introduction
The studies that have investigated the
relationship between metabolic
disorders, mastitis, and reproduction,
have only established associations and
were unable to infer causality
Milk Fever
Ketosis
Mastitis
4. Hypocalcemia
5.9% of U.S. Cows Subclinically
(NAHMS, 1996)
present in up to 50-
65% of fresh cows
Ketosis: 23.6 X
Smooth Muscle
Dystocia: 3 to7 X function
Release of cortisol
Retains: 4 X
accompanies (
Mastitis: 5 to 8 X immune function)
K and Na alkalinize
DA: 2 to 4 X blood and alter Ca
Associate costs to producer ~$300
5. Milk Fever and Reproduction
Fourichon et al., (2000):
Days to 1st Service ↑ 5 days
Services per Conception ↑ 0.3 services
Days open & conception to AI No Change
Chebel et al., (2004):
Risk of Conception ↓ 2.25 X
6. Mechanism(s) of Action
Alteration in uterine muscle function
Slower uterine involution
Reduced blood flow to the ovaries
Indirect effects:
dystocia
retained placenta
endometritis
reviewed in Mulligan et al., (2006)
7. Plan of Action
Feed a balanced ration, especially during
the close-up period (3 to 4 weeks before
calving)
Feed a balanced ration balanced for
dietary cation-anion difference (DCAD)
Feed dietary potassium at recommended
levels
Feeding anionic salts may be considered.
8. Ketosis
Prevalence:
12 to 14% in North American dairy cows
7 to 32% worldwide (reviewed in Cook et al., 2001)
Etiology:
marked glucose insufficiency
increased fat mobilization
Increase in blood ketone bodies
9. Decrease in feed intake
(2 wks before and 3 wks after calving)
Mobilization of body fat
Increase in blood fatty acids
1) - EB & 2) Stress of calving
Liver overload and inhibition of FA oxidation
Accumulation of triglycerides within hepatocytes
Increased conversion of acetyl-CoA to
acetoacetate and -hydroxybutyrate
10. Ketosis and Reproduction
Fourichon et al., (2000):
Days to 1st Service ↑ 2.5 days
Days open ↑ 6 days
Conception to 1st service ↓ ~ 4%
Hazard ratio of
conception (56 to 120
days postpartum)
↓ 13.5 %
The effects of clinical ketosis on reproduction are
limited and show large variation in different
production systems.
11. Ketosis and Reproduction
Cook et al., (2001):
Days open ↑ 54 days
Increased Culling rate
Walsh et al., (2007):
Increased BHBA
↓ 50% likelihood
of pregnancy to
(1st-2nd wk postpartum)
1st AI
12. Health Problems in the First 60 DIM and
Pregnancy in Dairy Cows
Pregnant,
Health status Adjusted OR (95% CI) P
%
Healthy 51.4 1.00
Type of health problem
Calving problem 40.3 0.75 (0.63 – 0.88) < 0.001
Metritis 37.8 0.66 (0.56 – 0.78) < 0.001
Clinical endometritis 38.7 0.62 (0.52 – 0.74) < 0.001
Fever postpartum 39.8 0.60 (0.48 – 0.65) < 0.001
Mastitis 39.4 0.84 (0.64 – 1.10) 0.20
Clinical ketosis 28.8 0.50 (0.36 – 0.68) < 0.001
Lameness 33.3 0.57 (0.41 – 0.78) < 0.001
Pneumonia 32.4 0.63 (0.32 – 1.27) 0.20
Digestive problem 36.7 0.78 (0.46 – 1.34) 0.38
5,719 postpartum dairy cows evaluated daily for health disorders in seven dairy farms in the US
13. Health Problems and Pregnancy Loss in the First
60 d of Gestation in Dairy Cows
Health status Loss, % Adjusted OR (95% CI) P
Healthy 8.9 1.00 ---
Type of health problem
Calving problem 15.9 1.67 (1.16 – 2.40) < 0.01
Metritis 11.3 1.01 (0.71 – 1.60) 0.76
Clinical endometritis 15.1 1.55 (1.04 – 2.32) 0.03
Fever postpartum 18.0 2.00 (1.24 – 3.14) < 0.01
Mastitis 19.8 2.62 (1.48 – 4.64) < 0.001
Clinical ketosis 14.6 1.64 (0.75 – 3.59) 0.22
Lameness 26.4 2.67 (1.38 – 5.12) < 0.01
Pneumonia 16.7 1.87 (0.40 – 8.69) 0.42
Digestive problem 15.8 1.81 (0.52 – 6.32) 0.35
5,719 postpartum dairy cows evaluated daily for health disorders in seven dairy farms in the US.
14. Plan of Action
Provide adequate dietary energy
Minimize the reduction of dry matter intake
during the last 3 weeks prepartum
Maximize dry matter intake after calving
Avoid overcrowding cows, especially in fresh
cow pen
Feeding additives such as niacin, calcium
propionate, propylene glycol, and rumen-
protected fat or choline, may be considered
15.
16. Milk Fever Ketosis
Muscle Function Ovarian Blood GI Motility
Flow
Uterine Motility
DMI and Ca2+ Absorption
Dystocia Retained Placenta
(−)
BHBA
Uterine Infection
(−)
[ Fatty Liver
− EB
Inflammation
Cytokines
(−) (−)
(TNFα, IL’s., etc.)
(−)
Oocyte maturations, embryo
(−) Fertility
fertilization and development
Figure 1. Potential mechanisms by which milk fever and ketosis affect fertility.
17. Mastitis
Definition:
Inflammation of the mammary gland
• trauma and (or) injury to the udder,
• infection due to microorganisms or chemical
irritation
Symptoms:
• decreased milk production
• alterations in milk composition and
appearance
• elevated body temperature
• swelling, redness, heat in infected quarters
and pain
18. Estimated Losses Due to Mastitis Once a Year
Item Dollar Loss per Cow
Reduced milk production $55 -121
Early cow replacement cost $30 - 40
Discarded milk $11- 35
Extra labor $1- 3
Drugs $7 - 12
Veterinary service $2 - 3
Total $106 - 214
Source: Winning the Fight Against Mastitis
Loss due to reproductive inefficiency
19. Percentage of cows by producer-
identified health problems
Health problem Incidence rate
(% of cows)
Clinical mastitis 16.5
Lameness 14.0
Retained placenta 7.8
Dystocia, metritis 3.8
Milk fever 4.9
Displaced abomasum 3.5
Ketosis* 3.7
NAHMS, 2007 *From Jordan and Fourdraine, 1993
20. Change in health problems
1996 to 2007
18
16 1996
14 2002
12
Percentage
2007
10
8
6
4
2
0
Mastitis Lameness RP Dystocia Milk DA
fever
21. Does mastitis affect other physiological
functions?
Thecost of mastitis reaches far beyond
the associated milk loss, drug and
veterinary costs, and labor
Recent studies confirm that mastitis
has detrimental effects on reproductive
efficiency of dairy cows
22. Mastitis and Reproductive Performance
Moore et al., (1991):
Negative correlation between clinical
mastitis and reproduction caused by
gram positive bacteria
Cows experiencing clinical mastitis
were 1.6 times more likely to have an
altered inter-estrus interval than
healthy cows
23. Effects of Mastitis Type Before First Insemination on
DFS, DO, and S/C
Black : clinical; Gray : subclinical
Striped: subclinical to clinical Hatched: uninfected
Schrick et al. (2001)
24. Clinical Mastitis and Abortion
Risco et al., (1999):
Infected cows within the first 45 days of
gestation were at 2.7 times more risk of
abortion as compared with uninfected
cows
Chebel et al., (2004):
Cows having clinical mastitis between AI
and pregnancy confirmation were 2.8
times more likely to have an abortion than
those not experiencing mastitis
25. The effect of mastitis on reproductive performance in dairy cows
Source Reproductive Parameters Mastitis Uninfected
Barker et al. (1998a) Days open 114 10 92 4.6
S/C 1.6 0.3 1.7 0.1
Barker et al. (1998b) Days open 136 11 92 4.6
S/C 2.9 0.3 1.7 0.1
Schrick et al. (2001) Days open 110 6.9 85.4 5.8
S/C 2.1 0.2 1.6 0.2
Conception rate 48% 63%
Kelton et al. (2001) Conception rate 38% 46%
Santos et al. (2003a) Days open 165 5.7 140 3.7
S/C 2.6 0.1 2.6 0.1
Conception rate at 1st AI 22% 29%
Santos et al. (2003b) Days open 189 7.2 140 3.7
S/C 3 0.2 2.6 0.1
Conception rate at 1st AI 10% 29%
26. The effect of mastitis on reproductive performance in dairy cows
Source Reproductive Mastitis Uninfected
Parameters
Nava-Trujillo et al.
(2010 c)
Days open 187 8.6 144 7.5
S/C 2.35 0.2 2.21 0.2
Conception rate at 1st AI 49% 56%
Hertle et al. (2010) Gram negative infection: 80%
reduction in probability of
conception, if infection occurred
in the week after AI
Probability of conception Gram positive infection: 47%
reduction in probability of
conception, if infection occurred
in the week after AI
c. dual purpose breed under tropical condition
27. The Effect Of Mastitis on
Reproductive Performance in Dairy
Cows
Reproductive Mastitis Uninfected
Parameters
Days open 160 days 126 days
S/C 2.4 2.1
Conception rate 10 – 49 % 29 – 63 %
28. Health Problems in the First 60 DIM and
Pregnancy in Dairy Cows
Pregnant,
Health status Adjusted OR (95% CI) P
%
Healthy 51.4 1.00
Type of health problem
Calving problem 40.3 0.75 (0.63 – 0.88) < 0.001
Metritis 37.8 0.66 (0.56 – 0.78) < 0.001
Clinical endometritis 38.7 0.62 (0.52 – 0.74) < 0.001
Fever postpartum 39.8 0.60 (0.48 – 0.65) < 0.001
Mastitis 39.4 0.84 (0.64 – 1.10) 0.20
Clinical ketosis 28.8 0.50 (0.36 – 0.68) < 0.001
Lameness 33.3 0.57 (0.41 – 0.78) < 0.001
Pneumonia 32.4 0.63 (0.32 – 1.27) 0.20
Digestive problem 36.7 0.78 (0.46 – 1.34) 0.38
5,719 postpartum dairy cows evaluated daily for health disorders in seven dairy farms in the US
29. Health Problems and Pregnancy Loss in the First
60 d of Gestation in Dairy Cows
Health status Loss, % Adjusted OR (95% CI) P
Healthy 8.9 1.00 ---
Type of health problem
Calving problem 15.9 1.67 (1.16 – 2.40) < 0.01
Metritis 11.3 1.01 (0.71 – 1.60) 0.76
Clinical endometritis 15.1 1.55 (1.04 – 2.32) 0.03
Fever postpartum 18.0 2.00 (1.24 – 3.14) < 0.01
Mastitis 19.8 2.62 (1.48 – 4.64) < 0.001
Clinical ketosis 14.6 1.64 (0.75 – 3.59) 0.22
Lameness 26.4 2.67 (1.38 – 5.12) < 0.01
Pneumonia 16.7 1.87 (0.40 – 8.69) 0.42
Digestive problem 15.8 1.81 (0.52 – 6.32) 0.35
5,719 postpartum dairy cows evaluated daily for health disorders in seven dairy farms in the US.
30. Limitations
Previous field trial:
None of the mentioned studies provides
information on whether cows with mastitis
also experienced other diseases
Meta-analyses showed problems such as
RP, ovarian cysts, and metabolic disorders
negatively affected reproduction, but
mastitis had no effect on reproductive
performance Fourichon et al., (2000)
.
31. Study in Idaho
Objectives
To evaluate the effect of clinical mastitis and
(or) other diseases on reproductive
performance, and to test the effect of time of
clinical mastitis occurrence on reproductive
performance in Holstein cows
32. Materials and Methods
Records from 963 lactating Holstein cows
(commercial dairy farm in Southern Idaho)
Groups:
Group 1 (n=50): cows with clinical mastitis and diseases
Group 2 (n=154): cows with clinical mastitis only
Group 3 (n=187): cows with diseases other than mastitis
Group 4 (n=572): healthy cows
33. Effect of Group on Days Open
180 a
160 a
140 155
Days Open
120 140 b
100 b
80 97
88
60
40
20
0
Mastitis + Mastitis Diseases Healthy
Diseases
Groups
a,b Bars with different letters differ (P < 0.05).
34. Effect of Group on Services/Conception
a
3
Services/Conception
2.9 b
bc
2 c
2.1
1.9
1.6
1
0
Mastitis + Mastitis Diseases Healthy
Diseases
Groups
a,b,c Bars with different letters differ (P ≤ 0.05).
35. Effect of Group on Days in Milk at 1st Service
Days in Milk 1st Service
80
72
60 72 67
65
40
20
0
Mastitis + Mastitis Diseases Healthy
Diseases
Groups
36. Non-linear Regression for the Effect of Mastitis and Diseases
on the Proportion of Non-pregnant Cows by 224 DIM
100 MD
M
90
Predicted Proportion nonpregnant (%)
D
80 C
70
60
50
Healthy vs. MD and M
40
*Slope = P < 0.01
30 Asymptote = P < 0.01
20
10
0
56 77 98 119 140 161 182 203 224
Days in Milk Mast vs. Mast & Dis
Slope = P < 0.05
Asymptote = P > 0.5
37. Effect of Time of Clinical Mastitis
Occurrence on Days Open
200 *
180
175
*
140
150 *
Days Open
122
125
100 88
75
50
25
0
Mastitis < 60 d Mastitis 60-100 d Mastitis > 100 Healthy
Days Post-partum
* Different from healthy P < 0.01
38. Effect of Time of Clinical Mastitis
Occurrence on Services/Conception
*
Services/Conception
3
* 3.0
†
2 2.4
1.9
1.6
1
0
Mastitis < 60 d Mastitis 60-100 d Mastitis > 100 d Healthy
Days Post-partum
† Different from healthy P = 0.06
* Different from healthy P < 0.01
39. Probability of
Scenario Conception
3rd lactation cow, winter, 21%
after second AI
gram+ mastitis1 wk 11%
before 2nd AI
gram-negative mastitis 5%
in the wk after AI
Hertle et al. (2010)
40. The value of this difference in conception for
a given situation can easily be weighed
against the cost of resources including
semen cost (especially if sexed semen is
used) and labor as well as other management
considerations including stage of lactation,
milk yield, and number of AI.
43. Bottom Line
Clinical mastitis alone affects reproductive
performance and these effects are more
evident when cows experience both mastitis
and diseases
While producers should manage mastitis at all
times, extra attention should be taken when
clinical mastitis occurs during AI period and
pregnancy establishment
44. Take Home Message
The e disorders can increase the risk of other
metabolic disorders as well as several
reproductive maladies such as dystocia, retained
placenta, and metritis
Disease prevention is the key to success.
Producers, veterinarians, nutritionists and farm
consultants should not only focus on disease
outcomes, but also review 'up-stream' factors
such as management practices, nutritional
regimens and health status, especially during the
transition period
45. Be Aggressive in Systematic
Breeding Protocol
Initiation of the
Set up injection protocol 1st Breeding
~ 50 days ~ 75 days
in milk ~ 65 days, VWP in milk
46. Extra Attention to
Completion of Milking and Mastitis
Breeding Protocol
and AI
Management
Post-AI Until Pregnancy conformation
(~ 45 days)